Kevin Horgan has been appointed executive vice president and chief medical officer of Seres Therapeutics (NASDAQ: MCRB). Horgan succeeds Michele Trucksis, who will continue to consult for the Cambridge, MA, microbiome drugs developer. Seres gave no reason for Tucksis’s departure. In a securities filing, the company said that she gave notice of her resignation on Oct. 17 and will remain employed at Seres through Nov. 16.
Horgan was most recently vice president of clinical development at AstraZeneca (NYSE: AZN). His experience also includes co-founding microbiome diagnostics company Tucana Health. Seres’s lead drug candidate, an experimental treatment for Clostridium difficile infection, is in late-stage clinical testing.